

### **REMARKS**

With the cancellation of the foregoing claims, the only active claims in this patent application are the ones which were deemed to be allowable in the Office Action of August 13, 2002. Additionally, Claim 16 is clarified in response to a teleconference with Examiner Owens on October 2, 2003.

MARKED UP VERSION OF CLAIM 16 -

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**


16. (Amended) A method of decreasing atherosclerosis comprising administering to a human or an animal in need thereof an amount of a substance selected from the group consisting of leuprolide acetate, goserelin acetate, flutamide, bicalutamide, and nilutamide, which is an inhibitor of the release of LHRH or GnRH resulting in decreased levels of LH.

Respectfully submitted,

CAESAR, RIVISE, BERNSTEIN  
COHEN & POKOTILOW, LTD.

October 7, 2003

By:

  
\_\_\_\_\_  
Kevin A. Keeling  
Registration No. 51,867  
Seven Penn Center - 12<sup>th</sup> Floor  
1635 Market Street  
Philadelphia, PA 19103-2212  
(215) 567-2010  
Attorney for Applicant  
Customer Number 03000

**CERTIFICATE OF MAILING**

I hereby certify that the foregoing **AMENDMENT ACCOMPANYING THE FILING  
OF REQUEST FOR CONTINUED EXAMINATION** re Application Serial No. 09/089,583 is being  
deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope  
addressed to: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-  
1450 on October 7, 2003

  
\_\_\_\_\_  
Kevin A. Keeling